CHMP backs Roche’s Enspryng for rare nerve disease NMOSDRoche’s Enspryng has been recommended for approval in the EU for treating neuromyelitis optica spectrum disorder (NMOSD), extending Share XCHMP backs Roche’s Enspryng for rare nerve disease NMOSDhttps://pharmaphorum.com/news/chmp-backs-roches-enspryng-for-rare-nerve-disease-nmosd/
CHMP backs Celltrion’s regdanvimab antibody for COVID-19The EU looks set to approve emergency use of a third antibody therapy for COVID-19 after its human Share XCHMP backs Celltrion’s regdanvimab antibody for COVID-19https://pharmaphorum.com/news/chmp-backs-celltrions-regdanvimab-antibody-for-covid-19/
J&J’s COVID-19 shot backed for emergency use in EUThe EU’s medicines regulator has recommended granting conditional approval to a fourth COVID-19 vaccine – a single-dose shot Share XJ&J’s COVID-19 shot backed for emergency use in EUhttps://pharmaphorum.com/news/jjs-covid-19-shot-backed-for-emergency-use-in-eu/
EMA backs emergency use of Lilly’s COVID antibodiesThe EMA’s human medicines committee has said two Eli Lilly antibodies are effective in people with COVID-19 who Share XEMA backs emergency use of Lilly’s COVID antibodieshttps://pharmaphorum.com/news/ema-backs-emergency-use-of-lillys-covid-antibodies/
CHMP clears way for EU approval of Novartis’ MS drugNovartis’ multiple sclerosis drug has been given the green light by the European Medicines Agency’s CHMP scientific committee, Share XCHMP clears way for EU approval of Novartis’ MS drughttps://pharmaphorum.com/news/chmp-clears-way-for-eu-approval-for-novartis-ms-drug/
EMA approves AZ’s COVID-19 vaccine – including for over-65sThe EMA has approved AstraZeneca’s COVID-19 vaccine for use in the EU in all adults aged over 18, Share XEMA approves AZ’s COVID-19 vaccine – including for over-65shttps://pharmaphorum.com/news/ema-approves-azs-covid-19-vaccine-including-for-over-65s/
Daiichi Sankyo, AZ close on EU approval of Enhertu for breast cancerDaiichi Sankyo and AstraZeneca could be just weeks away from an EU approval for their antibody-drug conjugate (ADC) Share XDaiichi Sankyo, AZ close on EU approval of Enhertu for breast cancerhttps://pharmaphorum.com/news/daiichi-sankyo-az-close-on-eu-approval-of-enhertu-for-breast-cancer/
Roche’s Herceptin/Perjeta combo product nears EU approvalThe EMA’s human medicines committee has recommended approval of a fixed-dose combination of Roche’s breast cancer drugs Herceptin Share XRoche’s Herceptin/Perjeta combo product nears EU approvalhttps://pharmaphorum.com/news/roches-herceptin-perjeta-combo-product-nears-eu-approval/
Kite cues up first EMA okay for mantle cell lymphoma CAR-TGilead Sciences’ Kite Pharma unit is closing on approval of its second European approval for a CAR-T for Share XKite cues up first EMA okay for mantle cell lymphoma CAR-Thttps://pharmaphorum.com/news/kite-cues-up-first-ema-okay-for-mantle-cell-lymphoma-car-t/
